Bei Ke Cai Jing
Search documents
看2026|政邦智库高明勇:拐点时刻,寻找突围的“线头”
Bei Ke Cai Jing· 2025-12-31 04:01
站在"十五五"新程待启的关键时点,如何看待2026年的经济形势?2026年经济工作怎么干?新京报贝壳 财经推出《看2026:十五五·启新程》专题报道,汇聚监管部门、知名学者和领军企业家,解读政策脉 络,洞察趋势变化。 新京报贝壳财经:中央经济工作会议提出持续扩大内需、优化供给,做优增量、盘活存量,因地制宜发 展新质生产力,对此,政邦智库会有哪些具体举措? 高明勇:政邦智库将聚焦城市品牌与企业咨询,围绕新质生产力和文化软实力,着力提升服务对象的软 实力、生长力和生命力。 政邦智库理事长高明勇。受访者供图 第一,强化"跨学科"服务能力。经济环境日趋复杂,智库产品更需要侧重提升解决问题的能力,这就要 求我们超越单维学科思维,整合跨领域资源,提供立体化的过程咨询。 第二,推出"一站式"咨询服务。在标准产品体系中,我们既会增加"定制化"差异化产品,也要强化"一 站式"服务的有效性。无论是城市还是企业,其资源禀赋、产业基础与发展阶段各不相同,提供优质服 务的关键,在于通过有效调研,挖掘深度诉求,从而做到因地制宜,精准施策。 第三,保持"动态性"实时监测。在新的发展阶段,智库服务将不止于提供定制路径方案,还将通过"政 企产 ...
看2026|科旭威尔谢先运:锚定50%增长目标 拓展大众市场
Bei Ke Cai Jing· 2025-12-31 04:01
站在"十五五"新程待启的关键时点,如何看待2026年的经济形势?2026年经济工作怎么干?新京报贝壳财经推出《看2026:十五五·启新程》专题报道,汇 聚监管部门、知名学者和领军企业家,解读政策脉络,洞察趋势变化。 编辑 岳彩周 校对 柳宝庆 北京科旭威尔科技股份有限公司董事长谢先运。受访者供图 谢先运:我们将依托在专业市场的技术沉淀与品牌优势,加快开发AI产品,并借助大模型能力持续降低服务成本,以更好地开拓大众市场。同时,我们也 将把握机遇拓展文旅市场,为消费者在文旅场景中提供创新的视频消费体验。 新京报贝壳财经:2026年,公司在业绩增长、产品创新、业务线等方面有何战略发展目标? 谢先运:为实现50%的业绩增长目标,2026年公司将在持续巩固专业市场头部地位的基础上,进一步向垂直应用领域深化布局。同时,公司将加快推进大众 类产品的研发与市场拓展,积极开拓具有相似需求的大众应用场景。 新京报贝壳财经记者 丁爽 对于企业而言,针对中央经济工作会议提出的持续扩大内需等议题会有哪些举措?2026年有哪些战略发展目标?新京报贝壳财经记者就此采访了北京科旭威 尔科技股份有限公司董事长谢先运。 新京报贝壳财经:中央经济 ...
打卡北京小巨人|利亚德集团孙铮:要积极做场景化创新应对国际竞争
Bei Ke Cai Jing· 2025-12-31 03:15
新 京 报 √ 贝壳财经 打卡北京小巨人 利亚德集团孙铮: 市场同质化竞争相对严重 时,要积极做场景化创新 应对国际竞争,不断推出 差异化产品和服务,引领 行业。 144 贝壳财经深入企业调研采访,利亚德集团产品总监孙铮对记者表示,市场同质化竞争相对严重时,要积极做场景化创新应对国际竞争,不断推出差异化产品 和服务,引领行业。 中国互联网发展基金会中国正能量网络传播专项基金支持 2025中国向上·新质先锋 新闻 校对 柳宝庆 "十五五"时期是我国基本实现社会主义现代化夯实基础、全面发力的关键时期。《中共中央关于制定国民经济和社会发展第十五个五年规划的建议》(以下 简称《建议》明确指出,必须坚持开放合作、互利共赢,通过推进标准更高、引领更强、联通更好、合作更深、保障更足的开放,来应对挑战、赢得战略主 动。 ...
雷军因感冒推迟跨年直播,抽送15台小米17 Ultra
Bei Ke Cai Jing· 2025-12-31 03:13
【#雷军就推迟直播道歉#】12月31日消息,小米科技创始人雷军今天上午在网络社交平平台表示,因为 感冒有点严重,原定跨年的直播推迟到1月3日晚7点,并表示,在微博抽送15台小米17 Ultra。雷军在回 复网友评论时表示,实在抱歉。网友回复称,"好饭不怕晚","好好休息早日康复"。#雷军跨年直播推 迟# 雷军之前通过社交平台宣布,将于跨年夜当晚开启一场特别的直播活动,直播期间将安排工程师现场拆 解小米汽车,"将满足大家的好奇心,通过专业拆解深度解析技术细节。" 据悉,这次直播将首次公开YU7的部分设计细节。雷军表示,除了技术解析环节,还会设置互动问答时 段,观众可通过弹幕提交关于小米汽车的各种疑问。技术团队已提前收集了数百个高频问题,准备在直 播中逐一解答。(新浪科技) ...
明德生物拟现金收购必凯尔全部股权
Bei Ke Cai Jing· 2025-12-31 02:40
Core Viewpoint - Mingde Biological (002932) has signed a share acquisition intention agreement with Bluefan Medical (002382) to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., Ltd. in cash, which is expected to constitute a major asset restructuring without involving a restructuring listing or issuing shares [1] Group 1: Company Overview - Bikaier is one of the earliest companies in China to introduce the international First Aid concept and technology [1] - The core business of Bikaier focuses on first aid kits, and it has expanded its offerings to include emergency equipment, individual emergency products, and emergency services related to rescue [1] Group 2: Transaction Details - The transaction will result in Bikaier becoming a wholly-owned subsidiary of Mingde Biological upon completion [1] - The acquisition is significant as it enhances Mingde Biological's capabilities in the emergency rescue sector [1]
盛新锂能:子公司拟20.8亿元收购启成矿业30%股权
Bei Ke Cai Jing· 2025-12-31 02:40
新京报贝壳财经讯12月30日,盛新锂能(002240)发布公告称,公司拟通过全资子公司盛屯锂业以现金 20.8亿元收购四川启成矿业有限公司(简称"启成矿业")30%股权,交易完成后,公司持有启成矿业100% 股权。盛屯锂业和启成矿业分别持有惠绒矿业15.10%和70.97%股权。惠绒矿业拥有木绒锂矿的采矿权 证,木绒锂矿已查明Li2O资源量98.96万吨,平均品位1.62%,为四川地区锂矿品位最高的矿山之一,生 产规模为300万吨/年,目前正在积极推进矿山开发建设。 ...
东杰智能:终止筹划重大资产重组,股票今起复牌
Bei Ke Cai Jing· 2025-12-31 02:39
新京报贝壳财经讯 12月30日,东杰智能发布公告称,公司决定终止筹划发行股份及支付现金购买遨博 (北京)智能科技股份有限公司控股权并配套募集资金的重大资产重组事项。公司股票将于2025年12月 31日开市起复牌,并承诺自公告披露之日起1个月内不再筹划重大资产重组。本次交易尚处于筹划阶 段,相关议案尚未提交公司董事会及股东会审议,重组事项尚未正式实施,交易双方对终止本次重大资 产重组无需承担任何违约责任。本次终止筹划重大资产重组事项不会对公司业务开展、生产经营活动和 财务状况造成不利影响。 ...
“感冒有点严重”,雷军推迟跨年直播拆车
Bei Ke Cai Jing· 2025-12-31 02:01
校对 陈荻雁 编辑 杨娟娟 新京报贝壳财经讯(记者陈维城)12月31日上午,小米创始人、董事长兼CEO雷军发文表示,"实在抱 歉,我感冒有点严重,原定跨年的直播只能推迟到 1月3日晚7点。" 早前一天,雷军宣布,将于12月31日晚8点做一场跨年直播,"前几天我在网上看过一个拆SU7视频,很 多人建议拆拆YU7。这次直播,我请工程师现场拆车,一边拆车一边聊。" ...
旭辉境外债务重组生效 碧桂园、融创、旭辉“三巨头”化债上岸
Bei Ke Cai Jing· 2025-12-31 01:49
Core Viewpoint - CIFI Holdings has successfully completed its offshore debt restructuring, becoming one of the first private real estate companies to achieve overall debt restructuring, following similar actions by major players like Country Garden and Sunac [1][7]. Group 1: Debt Restructuring - CIFI's offshore debt restructuring involves a total principal and interest amount of approximately $8.1 billion (about 56.7 billion RMB), with an expected debt reduction of about 38 billion RMB, achieving a debt reduction ratio of 67% [1]. - The domestic debt restructuring involves 7 public market bonds totaling 10.06 billion RMB, with an expected debt reduction of over 5 billion RMB, providing a critical window for business recovery and operational improvement as no principal or interest payments are required for the next two years [1][2]. - CIFI's total interest-bearing debt is projected to decrease from 84.2 billion RMB in mid-2025 to around 50 billion RMB, with the debt structure shifting from "short-term high interest" to "long-term low interest," significantly lowering financial costs [2][8]. Group 2: Strategic Transformation - CIFI is transitioning from a "high leverage, high debt, high turnover" model to a "light asset, low debt, high quality" approach, focusing on three core areas: rental income, self-operated development, and real estate asset management [4]. - The company has implemented a detailed "five-step" strategic plan to restore its capital market credibility, expand light asset operations, and switch its profit model, ultimately aiming to restart shareholder returns [4]. - CIFI's development activities have contracted this year, prioritizing sales over land acquisition and streamlining its organizational structure to focus on five key regions [4]. Group 3: Market Context - The overall debt restructuring progress among private real estate companies has been significant, with many firms reducing debt pressure through restructuring methods [7]. - CIFI's debt reduction ratios are comparable to those of other major firms, with its offshore debt reduction ratio at 67%, while Sunac achieved a 100% reduction through full debt-to-equity swaps [7][8]. - The industry is shifting towards light asset operations, with many companies exploring new market opportunities and focusing on asset management and property operations as viable paths for recovery [9].
看2026|医策科技王晓梅:以技术创新与全球视野深化业务布局
Bei Ke Cai Jing· 2025-12-31 01:29
Core Insights - The article discusses the economic outlook for 2026 and the strategic initiatives companies should undertake in response to the central economic work conference's emphasis on expanding domestic demand and optimizing supply [1][2]. Company Initiatives - The company, Hangzhou Yicai Technology Co., focuses on addressing the supply-demand imbalance in the domestic pathology field, where there are only 21,000 pathologists nationwide, equating to 14.8 pathologists per million people, highlighting a significant shortage and uneven resource distribution [5]. - The core strategy involves upgrading pathology AI from an "efficiency tool" to a "capability tool," enabling AI to serve as a "super assistant" with professional decision-making capabilities [5]. - The company aims to accelerate the implementation of AI-assisted diagnostic scenarios in major hospitals and provide low-cost AI capabilities to grassroots healthcare providers, thereby enhancing diagnostic efficiency and reducing the risk of missed diagnoses [5]. Strategic Development Goals for 2026 - By 2026, the company plans to solidify its core businesses in pharmaceutical research pathology CRO services and medical diagnostic pathology AI solutions, focusing on technological innovation and global expansion [6]. - The company has developed the world's first digital pathology CRO platform for pharmaceutical research, offering end-to-end digital processes from sample to report, which supports quantitative and semi-quantitative analysis for decision-making [6]. - The product line will cover various AI applications across cellular, tissue, immune, and molecular disciplines, with the "Lingmou" multimodal pathology model already applied in numerous medical institutions, establishing industry and data barriers [6]. - The company aims to expand its pathology AI technology and solutions globally, leveraging successful case studies to introduce its products to over ten countries, thereby creating a competitive and culturally sensitive industry ecosystem [6].